Voxelotor
As of the edition of 20 October 2026, Voxelotor is a small molecule: withdrawn from the market in 2024; acts on HBA1; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2024
- Kind
- Small molecule
- Brand name
- Oxbryta
- First approved
- 25 November 2019 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Pfizer
- Withdrawn from market
- 1 January 2024 (in some regions)
- Registered trials
- 29, 13 stopped early
- Disease areas
- Blood and lymph; Inherited and neonatal; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product17 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 17 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Voxelotor.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HBA1 | Hemoglobin subunit alpha | P69905 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 1 | 0 | 1 |
| Phase 1 | 8 | 7 | 0 | 1 |
| Phase 2 | 10 | 3 | 0 | 6 |
| Phase 3 | 4 | 0 | 0 | 4 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 29 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Originator and Lead sponsor of trials | 2014 to now |